Takeda’s dengue vaccine TAK-003 (Qdenga) has received clearance from the Subject Expert Committee under the Drugs Controller General of India for use in individuals aged 4 to 60 years. The approval marks a significant step in India’s efforts to tackle the growing burden of Dengue.
About Qdenga
Qdenga (TAK-003) is a live attenuated tetravalent vaccine, designed to provide protection against all four dengue virus serotypes (DENV-1 to DENV-4). Importantly, it can be administered regardless of whether a person has had a prior dengue infection.
The vaccine has been evaluated in large global clinical trials involving over 28,000 participants and is already approved in more than 40 countries. Studies indicate that it offers strong protection against severe dengue and hospitalisation, which are critical outcomes in managing the disease.
About Dengue
Dengue, a mosquito-borne viral infection, remains a major health concern in India, with rising cases across seasons. The presence of four distinct serotypes makes vaccine development particularly challenging, as immunity to one serotype does not ensure protection against others and may even increase the risk of severe illness upon reinfection.
![](https://www.gstimes.in/wp-content/uploads/2024/03/MARCH-2024-GS-TIMES-1ADD.jpg")
